

Cytomegalovirus Infection and Glutamic Acid Decarboxylase Antibodies in Type 2 Diabetic patients

RANATALIB AI-NAFAKH¹, SAIFJABBARYASIR², SHAYMAA ABDUL LTEEF AL-FADHUL², EKHLAS SABAH HASSAN³

¹Lecture, Department of Medical Microbiology, Faculty of Medicine, University of Kufa, Najaf, Iraq.

²Assistant Professor, Department of Medical Microbiology, Faculty of Medicine, University of Kufa, Najaf, Iraq.

³Assistant Professor, Specialist in Internal Medicine, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq.

Correspondence to Dr. Ekhlash Sabah Hassan, E- mail: ekhlash.khazaal@uokufa.edu.iq, Phone: 009647803012849

ABSTRACT

Background: At present, whether human cytomegalovirus (HCMV) infection is associated with type 2 diabetes mellitus (T2DM) is debatable.

Aim: To obtain information about the prevalence of CMV IgG antibodies among type 2 diabetic patients and to identify age, gender, and laboratory differences.

Methods: This cross-sectional study was carried out among DM type2. Seven hundred eighty-three sera type 2 diabetic patients were tested for the presence of HCMV-IgM&IgG antibodies, GAD, and cytomegalovirus DNA by PCR. Chi-square test (χ^2 -test) was applied for testing the significant association between different variables.

Results: The study included 783 diagnosed cases of type 2 diabetic mellitus, 261 of them (33%) were HCMV-IgG positive. Further investigations of HCMV-IgG seropositive samples revealed that 121(46%) tested positive to HCMV-IgM with a significant statistical differences of HCMV IgM within gender ($P=0.02$) and age groups ($P<0.001$). PCR test for diagnosis of HCMV showed that 81(31%) of samples were positive. Searching for presence of GAD antibodies in all HCMV IgG positive samples revealed that 100(38%) of patients were tested positive, however, statistically there was no significant association between positive anti-GAD antibodies with age groups and gender ($P>0.05$).

Conclusion: Our study determined that the higher prevalence of HCMV IgG in DM2 patients, depending on the results of IgM & PCR testes, more than one-third of HCMV IgG seropositive were having recent HCMV infection, about one-third of type two diabetic patient were tested positive to anti-GAD antibodies.

Keywords: HCMV, type 2 DM, anti-GAD antibodies,

INTRODUCTION

The worldwide prevalence of type 2 diabetes mellitus (T2DM) is estimated to have multiplied over the past decades and now includes rapidly increasing numbers of younger age groups. The condition is considerably more complex with much earlier onset, since there is a higher overall risk of life-time complications [1]. T2DM prevalence has risen faster in low and middle-income countries than in high-income countries². Cytomegalovirus (CMV) is a virus found around the world. It is a ubiquitous beta-herpes virus and herpesviridae that infects the majority of humans³. It is a common virus that infects people of all ages. CMV infection is commonly asymptomatic in healthy individual, but can cause severe disease in immunocompromised children or adults and in newborn. A person can also be re-infected with a different strain (variety) of the virus⁴. Active CMV infection or reactivation from a latent state is considered potentially a cofactor for inflammatory disease [5]. CMV may accelerate immune responses by prompting the accumulation of late-differentiated CD8+ and CD4+ T-cells which produce pro-inflammatory cytokines and thereby create a more pro-inflammatory background that might be causing T2DM onset⁶. A Glutamic Acid Decarboxylase (GAD) is an enzyme that present in the pancreas and the nervous system, its aids the body produce a specific neurotransmitter called gamma-aminobutyric acid (GABA), which is an amino acid that decreases the extent of communication to and from the nerves. GAD can also trigger the immune system to produce autoantibodies

against healthy cells⁷. GAD antibodies test is helping to discover whether someone has either Latent Autoimmune Diabetes of Adulthood (LADA) or type 1 diabetes. The test is done to define which type of diabetes someone has. It is particularly useful for adults more than 30 years who get diabetes where diagnosis of T2DM is uncertain⁸. This research aims to obtain information about the prevalence of CMV IgG antibodies among type 2 diabetic patients and to identify age, gender, and laboratory differences.

MATERIALS AND METHOD

This was a cross-sectional study that conducted in diabetes and endocrine gland center in AL-Sader teaching hospital in Al-Najaf Province during the period from January to July 2019. The cases were ascertained as type 2 DM and checked through their hospital records. All type 2 diabetic patients attended the diabetic outpatient clinic during the period of the study were included.

We tested seven hundred eighty-three sera from type 2 diabetic patients aged from 20 to 70 years, two hundred sixty-one of them were found positive for HCMV. IgG sero positive samples were collected to determine glutamic acid decarboxylase (GAD) antibodies and HCMV IgM antibodies. Anti-GAD antibody and specific anti-cytomegalovirus antibody (IgG and IgM) were detected by the ELISA test kit. (BioCheck, Inc.). Wholly blood samples with EDTA were detecting cytomegalovirus DNA. DNA extraction kit and PCR amplification kit are (DNA –Sorb-B) where supplied by Sacaca Biotechnology, Italy. DNA isolation and PCR amplification and thermocycling

conditions and procedures were done according to the instruction of the kit. The PCR product was amplified and detected by ethidium bromide staining visualization in agarose gel electrophoresis. The researcher took approval from Al-Najaf Health Directorate before the collection of data. The purpose of the research was clarified to all participants and formal consent was taken from them.

Statistical analysis: Data were stored and analyzed through the Statistical Package for the Social Science, SPSS (version 20) program. The results were represented through tables and graphs including frequency and percentage. Chi-square test (χ^2 -test) was applied for testing the significant association between different categorical variables. Statistical significance was considered if the p-value equal to or less than 0.05.

RESULTS

The studied sample comprised 783 type 2 diabetic patients, 33% of them (261/783) were HCMV IgG positive. Their ages ranged from 20 to 69 years, about one-third of them (32.2%) were within the age group (50-59) years. The results showed that 121 (46%) of the patients seropositive to HCMV-IgM antibody, whereas 81 (31%), and 100 (38%) of patients were tested positive to GAD antibody, and PCR respectively (Table 1). Table (2) demonstrated that 76 (62.8%) of males and 45 (37.2%) of females were seropositive to GAD antibodies, although statistically there is no significant association ($P > 0.05$). Furthermore, testing of HCMV IgM positivity revealed that males were higher in frequency than females, 69.0% vs 31.0% with significant statistical difference ($P = 0.02$).

More than one third (40%) of HCMV IgM positive patients were within the age group (60-69) years, (figure 1). Statistical analysis showed a highly significant difference of HCMV IgM positivity between different age groups ($P < 0.001$). Seropositivity to GAD antibodies was highly observed within age groups (50-59), and (60-69) years (figure 2). However, there were no

statistical significant differences between different age groups and the result of GAD antibody testing ($p > 0.05$). PCR testing revealed that 100 patients are HCMV positive, who distributed within different age groups, more than one-quarter of them (28%) was within age group (50-59) years, (figure 3). Statistically, there were no significant differences between age groups according to the result of the PCR test ($P > 0.05$).

Table 1: Demographic and laboratory features of HCMV IgG Positive Diabetic patient (N=261).

Features	n	%age
Gender		
Male	159	61
Female	102	39
Age groups		
20 – 29	12	4.6
30 – 39	45	17.2
40 – 49	54	20.7
50 – 59	84	32.2
60 – 69	66	25.3
GAD antibody		
GAD +	81	31.0
GAD -	180	69.0
HCMV-IgM		
IgM +	121	46.0
IgM -	140	54.0
PCR		
PCR+	100	38.0
PCR-	161	62.0

Table 2: Comparison HCMV seropositive males and females according to the result of GAD, and HCMV IgM antibodies.

	Male%	Female%	X2	P value
GAD +	76 (62.8)	45 (37.2)	0.34	0.56
GAD -	83 (59.3)	57 (40.7)		
IgM +	83 (69.0)	38 (31.0)	5.58	0.02*
IgM -	76 (54.3)	64 (45.7)		
Total	159 (60.9)	102 (39.1)		

*significant

Figure 1 :The results of HCMV detection by IgM antibodies according to age groups.




Figure 2: The results of GAD diabetic patients antibodies according to age groups.





Figure 3: The results of HCMV detection by PCR test according to age groups.



DISCUSSION

CMV is a highly prevalent herpes virus that infects persons from 30% to 100% in worldwide populations⁹. The evidence of high prevalence of human cytomegalovirus (HCMV) infection in T2DM patients is the existing of HCMV DNA in b cells of pancreas suggests that viral infection plays a significant role in the establishment of T2DM¹⁰.

Our findings demonstrated that the high prevalence of CMV infections (33%) coincided with T2DM, which was similar to findings of other studies conducted in Iraq^{11,12} and globally^{13,14,15}. A previous research estimating anti-CMV

IgG found that a higher frequency of CMV seropositive status and titer among T2DM patients than healthy controls (OR, 2 to 12). Likewise, CMV seropositivity was related with higher glucose levels¹⁶. However, these researches may have substantial limitations and are underpowered due to rare CMV events, the small sample size, and because the specific subjects do not reflect the universal population.

The pathophysiological mechanisms of post-CMV T2DM stay questionable, in spite of the fact that researchers¹⁷ showed that CMV genes localized in the pancreatic islets of Langerhans cells without

cytopathic inflammation¹⁸. A recent study reported that direct pancreatic β -cell injury was associated with the immunologic consequences of CMV infection, supported by T lymphocyte infiltration¹⁹. The role of CMV infection in the development of T2DM could be due to direct and/or indirect pancreatic damages through the effect of CMV infection on the failure of islet allografts to support the active CMV replication²⁰. In contrast, the materials that used in the envelope components like viperin, was assumed to change the pathways of lipid and glucose metabolism²¹.

Researchers reported different evidences that support a possible relationship between CMV and diabetes. CMV nucleic acids have been demonstrated more often in the arterial walls of diabetic patients versus controls²². Also, CMV DNA has been identified in the pancreas of individuals with T2DM; however, it is uncertain whether CMV damages β cells in the pancreas and reduces insulin release, leading to diabetes, or whether diabetic persons are more prone to CMV infection²³. Another mechanism may be explained by immunological response to CMV infection, including T cells cross-reacting with a CMV-binding protein, activating cytokine production and inflammatory response²⁴.

The current research showed that higher HCMV IgG seropositivity among male beyond the age group (50-59) years this was similar to findings of previous studies^{11,12,14}.

In this study, HCMV-IgM was tested in all IgG seropositive type 2 diabetic patients, 46% of them were positive for IgM. which was similar to findings as those reported by Bertram & Irina²⁵. However; current results found that HCMV-IgM positive test was higher than PCR (46%) vs (38%), this could be attributed to False-positive IgM reactions that might be due to antigenic cross-reactivity among the herpes viruses, including CMV and EBV²⁶. Regarding gender distribution, Previous researches^{12,13} reported no significant differences in the rate of recent CMV infection among diabetic patients, current findings showed that HCMV IgM seropositivity was significantly higher in males than females (69%) vs (31%), ($P=0.02$).

Testing of HCMV IgM according to different age groups revealed that seropositivity was higher in percentage (40%) among the older age groups (60-69) years, statistically, there were significant differences of HCMV IgM between different age groups ($p<0.001$). This finding may be attributed to lower immunity in the older patients, or due to associated chronic conditions that play a role in decreasing the body's ability to resist the virus, Individuals remain infected for life with latent CMV, which have reactivated later¹².

According to the result of the PCR test, the highest percentage of CMV- DNA detection among age group (50-59) years than other age groups with no significant differences ($P>0.05$). The PCR is a reliable and applicable tool for the detection of HCMV in the blood of the diabetic patients. Quantitative PCR shows to be superior, faster and highly sensitive than measurement of antibodies titer for the diagnosis of CMV infection²⁷.

In the present study, GAD-Ab was tested in all HCMV IgG positive type 2 diabetic patients, the results showed that 31% of patients were positive for GAD which represents higher than findings of Iraqi research that recorded anti-GAD IgG frequency of 14.8%^[28]. Other

researches showed prevalence of anti-GAD IgG among type two DM ranged from 12.6% to 37%^[29]. Type 2 diabetic patients who were tested positive for GAD auto-antibody were distributed within different age groups with the highest percentage within age group (50-59) years, although there were no significant statistical association between CMV infection and age groups ($P>0.05$). One factor could be explained the current result that having inherited TCF7L2, which is the risk allele of the gene with the strongest relationship with T2DM, it has been found to reduce insulin secretion and it was as common in LADA as in T2DM³⁰.

The current research has important limitations. First, since it is a cross-sectional study so the temporal relationship cannot be inferred, we did not distinguish whether CMV infection occurs before or after type two DM. This research was more complicated by the using IgG seropositivity for diagnosis of CMV infection because IgG indicates an old infection, however, further confirmatory tests were done including PCR and IgM. Large sample size (783) type 2 diabetic patients is one of the strengths of this study.

CONCLUSION

High prevalence of HCMV IgG antibodies among type two diabetic patients, more than one-third of HCMV IgG seropositive were having recent HCMV infection depending on the results of IgM & PCR tests, there are gender and age differences in distribution of recent CMV infection, about one-third of type two diabetic patient were tested positive to anti-GAD antibodies, although there was no significant association with gender and age groups.

Conflicts of interest: None of the authors have any conflicts of interest relevant to this research subject.

Ethical clearance: The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki. The study protocol and subject information were reviewed and approved by a local Ethics Committee.

Funding Support: None.

REFERENCES

1. The Lancet. Type 2 diabetes: the urgent need to protect young people. *Lancet Diabetes Endocrinol* 2018.
2. Amy Bradshaw Kai Sser, Nicole Zhang and Wouter Van Der Pluijm. Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028). *Diabetes* 2018;67.
3. Hodinka, R. L. Human Cytomegalovirus. In P. R. Murray (Ed.), *Manual of clinical microbiology*. 2007;9thed.:1549-1563. Washington, D.C.: ASM Press.
4. Reasonable RR and Humar A. AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. *Am J Transplant*. 2013;13:93-106.
5. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? *J Intern Med*. 2006;259:219-246.
6. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, and Aiello AE. Seropositivity to cytomegalovirus, inflammation, all cause and cardiovascular disease-related mortality in the United States. *PLoS One*. 2011;6:e16103. 10.1196/annals.1396.043.
7. Tohid H. Anti-glutamic acid decarboxylase antibody positive neurological syndromes. *Neurosciences*. 2016;21:215-222.

8. Diabetes.co.uk-the global diabetes community© 2019 Diabetes Digital Media Ltd.
9. Cannon MJ, Schmid DS and Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev Med Virol.* 2010;20:202–213.
10. Roberts BW and Cech I. Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. *South Med J.* 2005; 98: 686–92.
11. Rahman Q Lajan, Hussain KhSaeed, Khudhur KH Pinar and Bakir A Amin. Glutamic acid decarboxylase-IgG among T2DM patients with HCMV infection and HbA1c levels. *Diyala Journal of Medicine.* 2018;14:49-55.
12. Kadhum E Jawad, Yasir S Jabbar and Shaalan A Atteya. Relationship between HCMV and Diabetic Mellitus Type 2 of Elderly Patients in Al-Najaf Governorate. *Journal of Global Pharma Technology.* 2019;11:09-14.
13. Yoo S, Han K, Lee K, La Y, Kwon D, and Han S. Impact of Cytomegalovirus Disease on New-Onset Type 2 Diabetes Mellitus: Population-Based Matched Case-Control Cohort Study. *Diabetes & Metabolism Journal.* 2019;43:1-15.
14. Schmidt L, Nelson HH, Thyagarajan B, Hunter-Schlichting D, Pankow JS, Capistrant B, et al. Association between cytomegalovirus seropositivity and Type 2 diabetes is explained by age and other demographic characteristics: the National Health and Nutrition Examination Survey. *Diabetic Medicine.* 2018;35:1722-1726.
15. Jun Zhang, Yuan-yuan Liu, Hui-ling Sun, Shan Li, Hai-rong Xiong, Zhan-qiu Yang, et al. High Human Cytomegalovirus IgG Level is Associated with Increased Incidence of Diabetic Atherosclerosis in Type 2 Diabetes Mellitus Patients. *Med Sci Monit.* 2015;21:4102-4110.
16. Chen S, de Craen AJ, Raz Y, Derhovanessian E, Vossen AC, Westendorp RG, et al. Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. *Immun Ageing.* 2012;9:18.
17. Lohr JM, and Oldstone MB. Detection of cytomegalovirus nucleic acid sequences in pancreas in type 2 diabetes. *Lancet.* 1990;336: 644-8.
18. Numazaki K, Goldman H, Wong I, and Wainberg MA. Viral infection of human fetal islets of Langerhans. Replication of human cytomegalovirus in cultured human fetal pancreatic islets. *Am J Clin Pathol.* 1988;90:52-7.
19. Yoneda S, Imagawa A, Fukui K, Uno S, Kozawa J, Sakai M, et al. A histological study of fulminant type 1 diabetes mellitus related to human cytomegalovirus reactivation. *J Clin Endocrinol Metab.* 2017;102:2394-400.
20. Eckhard M, Martin I, Eich T, Weimer R, Zinn S, Bretzel RG, et al. Incidence of cytomegalovirus infections after immunosuppression induction in clinical islet transplantation and impact on graft function. *Transplant Proc.* 2002;34:1922-4.
21. Seo JY, and Cresswell P. Viperin regulates cellular lipid metabolism during human cytomegalovirus infection. *PLoS Pathog.* 2013;9:e1003497.
22. Firth C, Harrison R, Ritchie S, Wardlaw J, Ferro C, Starr J, et al. Cytomegalovirus infection is associated with an increase in systolic blood pressure in older individuals. *QJM.* 2016;109:595-600.
23. Smelt MJ, Faas MM, de Haan BJ, Draijer C, Hugenholtz GC, de Haan A, et al. Susceptibility of human pancreatic β cells for cytomegalovirus infection and the effects on cellular immunogenicity. *Pancreas.* 2012;41:39-49.
24. Gaëlle Picarda and Chris A. Benedict. Cytomegalovirus: Shape-Shifting the Immune System. *J Immunol.* 2018; 200:3881-3889.
25. Bertram W. Roberts and Irina Cech. Association of Type 2 Diabetes Mellitus and Seroprevalence for Cytomegalovirus. *Southern Medical Journal.* 2005;98:686-92.
26. Sohn M, Cho J, Moon J, Ko J, and Yang H. EBV VCA IgM and cytomegalovirus IgM dual positivity is a false positive finding related to age and hepatic involvement of primary Epstein-Barr virus infection in children. *Medicine.* 2018;97:e12380.
27. Razonable RR and Humar A, AST Infectious Disease Community Practice. Cytomegalovirus in solid organ transplantation. *Am J Transplant.* 2013;13:93–106.
28. Jasem MA, Al-Ubaidi AA, Admona Z, and Waer KN. Prevalence of LADA among clinically diagnosis type 2 diabetic patients. *Med J. of Islamic World Academy of Sciences.* 2010;18:49-54.
29. Kim CS, Park J, Cho MH, Park JS, Nam JY, et al. Frequency of Anti-GAD antibody in non-obese, adult-onset type 2 diabetes in Korea clinical and biological characteristics according to anti-GAD antibody. *J Korean Diabetes Assoc.* 2004;28:66-74.
30. Storm A, Menrat B, Simon MC, Pham MN, Kolb H, Roden M, Pozzilli P, et al. Cellular interferon- γ and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: Action LADA 6. *Cytokine.* 2012;58:148-151.